Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ raptor resources limited

Ann: ResApp Provides Updated Paediatric Clinical Study Results, page-80

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 80 Last

Share
Profile

Follow
match_d

392 Posts.

1

04/04/16

15:08

Post #: 17417172
Share

Originally posted by RudeeOne ↑

Thanks Sammy. Attached is page 11 of the March presentation.

In my view these are the critical factors:
1. Result of the Adult Clinical Test - whether it mimics the Paeditrician's results
2. Uptake of Adult Clinical Test in USA
3. The FDA submission

Assuming we progress successfully to the FDA Approval, the share price could be anywhere from there. Sirtex's share price is currently around $30 with an annual revenue of $175 million. ResApp, in my view, has the potential to achieve similar revenue if not more over time.

With these in mind therefore the essence is to keep an eye closely on these critical factors. The rest, as usual, is just short term NOISE.

Expand

27.5 to 22c in a week is more than noise though? baffled by the drops...i thought it would hold as ppl should buy these stocks to get in

RAP Price at posting: 22.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

IMU

Imugene kicks off Australian trial for blood cancer treatment

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 37 more messages in this thread...

First 80 Last

Add RAP (ASX) to my watchlist